Analyst Ratings For Novavax (NASDAQ:NVAX)
Today, Citigroup reiterated its Neutral rating on Novavax (NASDAQ:NVAX) with a price target of $2.75.
Some recent analyst ratings include
- 2/20/2018-Citigroup Reiterated Rating of Neutral.
- 12/18/2017-Cantor Fitzgerald Reiterated Rating of Hold.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Neutral.
- 7/27/2017-Chardan Capital Reiterated Rating of Neutral.
Recent Insider Trading Activity For Novavax (NASDAQ:NVAX)
Novavax (NASDAQ:NVAX) has insider ownership of 4.00% and institutional ownership of 37.53%.
- On 1/31/2018 Gregory M. Glenn, Insider, bought 12,784 with an average share price of $0.88 per share and the total transaction amounting to $11,249.92.
- On 11/9/2017 Stanley C Erck, Insider, bought 100,000 with an average share price of $1.13 per share and the total transaction amounting to $113,000.00.
- On 8/31/2017 James F. Young, Director, sold 175,000 with an average share price of $1.06 per share and the total transaction amounting to $185,500.00.
- On 7/31/2017 Barclay A. Phillips, CFO, bought 2,057 with an average share price of $0.89 per share and the total transaction amounting to $1,830.73.
- On 5/12/2017 Michael A Mcmanus Jr, Director, bought 20,000 with an average share price of $0.97 per share and the total transaction amounting to $19,400.00.
- On 5/11/2017 Barclay A Phillips, CFO, bought 25,000 with an average share price of $0.84 per share and the total transaction amounting to $21,000.00.
- On 5/11/2017 Michael A Mcmanus Jr, Director, bought 10,000 with an average share price of $0.84 per share and the total transaction amounting to $8,400.00.
Recent Trading Activity for Novavax (NASDAQ:NVAX)
Shares of Novavax closed the previous trading session at 2.46 up +0.12 5.34% with 2.5999999046325684 shares trading hands.